pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
PUBLIC COMPANY
save

$IMNMImmunome Inc.

$IMNM26.42-5.61%
Bothell, WA, USupdated 5h ago

The immunome is the set of genes that code for proteins which constitute the immune system, excluding those that are widespread in other cell types, and not involved in the immune response itself. It is further defined as the set of peptides derived from the proteome that interact with the immune system. There are numerous ongoing efforts to characterize and sequence the immunomes of humans, mice, and elements of non-human primates.

Website ↗SEC EDGAR ↗Yahoo Finance ↗
community read0 votes
pipeline
3
marketed
0
phase 3
1
catalysts ytd
1
approvals ytd
0
recalls ytd
0

Pipeline(3)

pipeline depth3 products
Phase 1: 2Phase 3: 1
2Phase 11Phase 3
Phase 3
varegacestat
Desmoid Tumors
Phase 1
IM-1021
Diffuse Large B-Cell Lymphoma
Phase 1
IM-3050
Solid Tumor

📅 Upcoming

no upcoming catalysts on record

🕒 Recent(90d)

earnings (1)
Aug 10, 2026
earnings
$IMNM26.42-5.61%
4d ago
Immunome Inc. earnings
Immunome Inc.
→
view all catalysts →

Insider activity

source: SEC Form 4

open-market buys + sells

  • Apr 2, 26SELLRosett Max· Chief Financial Officer63,656 sh @ $21.91−$1.39M↗
  • Apr 2, 26SELLHiggins Jack· Chief Scientific Officer9,438 sh @ $21.64−$204K↗
  • Apr 2, 26SELLRosett Max· Chief Financial Officer1,344 sh @ $22.48−$30K↗
  • Mar 27, 26BUYSIEGALL CLAY B· President and CEO25,450 sh @ $19.67$501K↗
  • Mar 23, 26SELLWAGENHEIM PHILIP· 28,200 sh @ $20.65−$582K↗
  • Mar 20, 26SELLWAGENHEIM PHILIP· 36,800 sh @ $20.47−$753K↗
  • Mar 11, 26BUYBIENAIME JEAN JACQUES· 1,000 sh @ $21.55$22K↗
  • Mar 10, 26BUYBIENAIME JEAN JACQUES· 1,000 sh @ $22.12$22K↗
routine RSU / option mechanics (5)
  • Apr 2, 26option exerciseRosett Max · Chief Financial Officer39,713 sh
  • Apr 2, 26option exerciseRosett Max · Chief Financial Officer31,848 sh
  • Apr 2, 26option exerciseRosett Max · Chief Financial Officer39,713 sh
  • Apr 2, 26option exerciseRosett Max · Chief Financial Officer31,848 sh
  • Mar 30, 26giftHiggins Jack · Chief Scientific Officer6,291 sh
🐶 Hiring Signal
No open roles indexed yet — view Immunome Inc. jobs →

News

no news has mentioned this company yet
identifiers
ticker
$IMNM
SEC CIK
0001472012
country
US
source
sec_tickers
top tags
Oncology2DLBCL1NSCLC1Pulmonary Fibrosis1Pulmonology1
mentioned in
0news items
entity-linker matched
Data sources
SEC EDGAR
last refreshed 25m ago
Found something off?
🐶 something off?

Report a data issue

Tell Bork what looks wrong — wrong sponsor, stale phase, mislinked ticker, anything. We’ll triage and fix.

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?